pharma · Attention Deficit Disorder With Hyperactivity · Hidradenitis suppurativa (HS) · AVTX
Avalo Therapeutics
Avalo Therapeutics is a pharma organization headquartered in Chesterbrook, USA. It trades on NYSE under ticker AVTX. Primary therapeutic focus areas include Attention Deficit Disorder With Hyperactivity, Hidradenitis sup
1500 Liberty Ridge Dr, Chesterbrook, Pennsylvania 19087, US HQ
2011 Founded
48 Employees
Public company Type
AVTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1500 Liberty Ridge Dr, Chesterbrook, Pennsylvania 19087, US
- Founded
- 2011
- Employees
- 48
- Programs
- 17
- Drugs
- 2
- Patents
- 10
NFC-1
Phase 3 · small molecule · Attention Deficit Disorder With Hyperactivity
NFC-1 for Attention Deficit Disorder With Hyperactivity is a Phase 3 program (small_molecule) at Avalo Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code MDGN-NFC1-ADHD-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Avalo Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Attention Deficit Disorder With Hyperactivity
- Status
- completed
- Trials
- 1